Safety & Efficacy of DCR-PHXC in Patients With PH1/2 and ESRD — PHYOX7  

End Stage Renal Disease Clinical Trial

Official title: A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without Dialysis

Status Recruiting

Clinical Trial Summary

The aim of this study is to evaluate DCR-PHXC in participants with PH1 or PH2 and severe renal impairment, with or without dialysis.

Clinical Trial Description

This is an open-label, repeat-dose, Phase 2 study of DCR-PHXC in participants with PH1 or PH2 and severe renal impairment, with or without dialysis.

Following the up-to-35- day screening period, participants will return to the clinic for monthly dosing visits through Day 180. Participants successfully completing the Day 180 visit will continue on to an extended follow-up period and receive open-label DCR-PHXC for an additional 3 years, or until DCR-PHXC is commercially available, whichever comes first. As participants in this extended treatment period will return to the clinic only every 3 months, participants and/or their caregivers may be trained in the at-home administration of DCR-PHXC or home health nurses may assist with administration of DCR -PHXC.

The total duration of the study is approximately 2 years from first participant, first visit, to last participant, last Day 180 visit, with up to an additional 3 years of extended follow-up. ;

Related Conditions & MeSH terms

• End Stage Renal Disease
• Hyperoxaluria, Primary
• Kidney Failure, Chronic
• Primary Hyperoxaluria Type 1
• Primary Hyperoxaluria Type 2

• NCT number: NCT04580420
• Study type: Interventional
• Source: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
• Contact: Medical Information
• Phone: 617-621-8097
• Email: medicalinfo@dicerna.com
• Status: Recruiting
• Phase: Phase 2
• Start date: April 15, 2021
• Completion date: May 2025